Skip to main content
Tharimmune, Inc. logo

Tharimmune, Inc. — Investor Relations & Filings

Ticker · THAR ISIN · US4327051011 LEI · 52990040X8C60JYNXZ70 US Manufacturing
Filings indexed 286 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US THAR

About Tharimmune, Inc.

https://tharimmune.com/

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for immunology, inflammation, and oncology. The company's pipeline includes TH104, a product candidate for treating pruritus in primary biliary cholangitis (PBC), and treatments for solid tumors that target mechanisms such as ferroptosis. In addition to its biotechnology research and development, the company is also involved in activities supporting institutional blockchain adoption and the digitization of financial markets through the Canton Network.

Recent filings

Filing Released Lang Actions
10-Q - Canton Strategic Holdings, Inc. (0001861657) (Filer)
Interim / Quarterly Report
2026-05-13 English
10-K - Canton Strategic Holdings, Inc. (0001861657) (Filer)
Annual Report FY 2025
2026-03-31 English
8-K - Canton Strategic Holdings, Inc. (0001861657) (Filer)
Regulatory Filings
2026-03-31 English
8-K - THARIMMUNE, INC. (0001861657) (Filer)
Regulatory Filings
2026-03-03 English
8-K - THARIMMUNE, INC. (0001861657) (Filer)
Regulatory Filings
2026-03-03 English
8-K Filing
Regulatory Filings
2026-02-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.